REPORT TO THE LEGISLATURE
Pursuant to P.A. 121 of 2024
Section 607
FY 2025 Quarter 4
Michigan Department of Corrections

Sec. 607. (2) The department must submit quarterly reports on the status of establishment and operation of medication-assisted treatment clinics. A report under this subsection must include but not be limited to all of the following:
(a) Clinic site locations.
(b) Staffing levels.
(c) Expenditures on staffing and supplies, including oral and injectable medications.
(d) Number of prisoners treated.
(e) Number of prisoners requiring treatment but not yet receiving treatment.

Michigan Department of Corrections has 26 correctional facilities prescribing naltrexone and 17 of those correctional facilities are currently prescribing buprenorphine products for Medication Assisted Treatment (MAT) for those diagnosed with an Opioid Use Disorder. In the fourth quarter of FY25 the department continues to maintain the 17 previously implemented facilities.

The clinic site locations are Bellamy Creek Correctional Facility – Ionia, Carson City Correctional Facility– Carson City, Central Michigan Correctional Facility– St. Louis, Charles E. Egeler Reception and Guidance Center – Jackson, G. Robert Cotton Correctional Facility – Jackson, Gus Harrison Correctional Facility – Adrian, Ionia Correctional Facility – Ionia, Macomb Correctional Facility – New Haven, Marquette Branch Prison – Marquette, Muskegon Correctional Facility – Muskegon, Oaks Correctional Facility – Manistee, Parnall Correctional Facility – Jackson, Richard A. Handlon Correctional Facility – Ionia, St. Louis Correctional Facility – St. Louis, Thumb Correctional Facility – Lapeer, Women's Huron Valley Correctional Complex – Ypsilanti, and Woodland Correctional Facility – Whitmore Lake.

The information below is for the fourth quarter for FY25 and will be updated on a different report that will be sent as soon as we receive all invoices for September.

Site locations selected	Buprenorphine Sites	17
	Naltrexone Sites	26
	New MAT sites established	0
Staffing levels	Filled MAT Positions	63
	Vacant MAT Positions	8
Expenditure on staffing	**TOTAL COST:**	**$1,820,147.24**

Expenditures on supplies, including oral and injectable medications	Brixadi:	$348,944.40
	Suboxone:	$99,965.39
	Naltrexone:	$33,061.39
	TOTAL COST:	**$481,971.18**
Number of prisoners treated	Number of inmates that received at least 1 dose of MAT medication	
	TOTAL:	**2,320**
Number of prisoners requiring treatment but not yet receiving treatment	**TOTAL:**	**2,806**

Below are the updated expenses, staffing levels, and information from quarter three as we received all invoices after the quarter three report was submitted.

Site locations selected	Buprenorphine Sites	17
	Naltrexone Sites	26
	New MAT sites established	0
Staffing levels	Filled MAT Positions	64
	Vacant MAT Positions	7
Expenditure on staffing	**TOTAL COST:**	**$1,825,114.28**
Expenditures on supplies, including oral and injectable medications	Brixadi:	$491,904.00
	Suboxone:	$115,026.70
	Naltrexone:	$45,611.57
	TOTAL COST:	**$652,542.27**
Number of prisoners treated	Number of inmates that received at least 1 dose of MAT medication	
	TOTAL:	**2,195**
Number of prisoners requiring treatment but not yet receiving treatment	**TOTAL:**	**2,778**